Michael J. Morris, MD

Articles

Dr. Morris on Findings From the TheraP Study in mCRPC

August 19th 2021

Michael J. Morris, MD, discusses findings from the phase 2 TheraP study, and how they led to the development of the phase 3 VISION trial in metastatic castration-resistant prostate cancer.

Dr. Morris on the Efficacy of 177Lu-PSMA-617 Plus Best SOC in mCRPC

August 19th 2021

Michael J. Morris, MD, discusses the efficacy of Lutetium 177 PSMA-617 as a treatment for patients with metastatic castration-resistant prostate cancer.

Dr. Morris Discusses Ongoing Research With 177Lu-PSMA-617 in Prostate Cancer

July 28th 2021

Michael J. Morris, MD, discusses ongoing research efforts with 177Lu-PSMA-617 in prostate cancer.

Dr. Morris on Next Steps for PSMA–Targeted PET Imaging in Prostate Cancer

July 30th 2020

Michael J. Morris, MD, discusses next steps for prostate-specific membrane antigen–targeted PET imaging in prostate cancer.

Dr. Morris on the Design of the Phase 3 CONDOR Trials in Recurrent Prostate Cancer

July 9th 2020

Michael J. Morris, MD, discusses the ​design of the phase 3 CONDOR trial in men with biochemically recurrent prostate cancer.

Dr. Morris on Deciding Among PET Tracers in Prostate Cancer

June 19th 2020

Michael J. Morris, MD, discusses factors to consider when deciding among PET tracers in prostate cancer.

Dr. Morris on the Promise of PSMA-Targeted PET Imaging in Prostate Cancer

June 15th 2020

Michael J. Morris, MD, discusses the promising future of prostate-specific membrane antigen–targeted PET imaging in prostate cancer.

Dr. Morris on Impact of PSMA-Targeted Imaging on Clinical Management of Prostate Cancer

June 5th 2020

Michael J. Morris, MD, discusses the impact of prostate-specific membrane antigen-targeted imaging with 18F-DCFPyL-PET/CT on the clinical management of patients with prostate cancer.

Dr. Morris Discusses Biomarkers in Prostate Cancer

December 17th 2018

Michael J. Morris, MD, medical oncologist, clinical director, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses biomarkers in prostate cancer.

Dr. Morris Discusses PSMA-Targeted Imaging in mCRPC

November 20th 2018

Michael J. Morris, MD, medical oncologist, clinical director, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the use of prostate-specific membrane antigen (PSMA)-targeted imaging in patients with metastatic castration-resistant prostate cancer.

Dr. Morris on the Next Steps With Bone Biomarkers for Prostate Cancer

May 11th 2017

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses the next steps regarding bone biomarkers for patients with prostate cancer.

Dr. Morris on Challenges of Radium-223 Treatment in Prostate Cancer

February 23rd 2017

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with radium-223 treatment in prostate cancer.

Dr. Morris on Bone Biomarkers for Radium-223 in Prostate Cancer

February 18th 2017

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses bone biomarkers for radium-223 dichloride (Xofigo) in castration-resistant prostate cancer.

Dr. Michael J. Morris on Radium-223 Combination Options for mCRPC

December 2nd 2016

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses the benefits of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Morris on Novel Approaches With Radium-223 in mCRPC

November 18th 2016

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses what novel combinatorial approaches researchers will be explored with radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Morris on Mechanism of Action for Radium-223

January 27th 2016

Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the mechanism of action for radium-223 dichloride as a treatment for patients with prostate cancer.

Dr. Michael Morris on Combining and Sequencing Radium-223

November 13th 2015

Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combining radium-223 with other types of treatment and how to best optimize the use of the drug alone.

Dr. Morris on rPFS as an Endpoint in Clinical Trials

May 22nd 2013

Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the use of radiographic progression-free survival as an endpoint in prostate cancer clinical trials.

Dr. Morris Discusses PET Imaging in Prostate Cancer

May 16th 2013

Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the use of PET imaging for patients with prostate cancer.